The DLBCL variant of RS displays an immune phenotype different from the underlying CLL, showing loss of the surface markers CD5 and CD23 are lost in most cases of RS, while the expression of CD19 is invariably maintained (12). This evidence concerns the gene CD5 and B-cell chronic lymphocytic leukemia.